This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldkorn, A. Articles by Blackburn, E. H. Search for Related Content PubMed PubMed Citation Articles by Goldkorn, A. Articles by Blackburn, E. H.

Assembly of Mutant-Template Telomerase RNA into Catalytically Active Telomerase Ribonucleoprotein That Can Act on Telomeres Is Required for Apoptosis and Cell Cycle Arrest in Human Cancer Cells

¹ Department of Internal Medicine, Division of Hematology and Oncology and ² Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, California

Requests for reprints: Elizabeth H. Blackburn, Department of Biochemistry and Biophysics, University of California at San Francisco, San Francisco, CA 94143-2200. Phone: 415-476-4912; Fax: 415-514-2913; E-mail: elizabeth.blackburn{at}ucsf.edu.

The telomerase ribonucleoprotein is a promising target for cancer therapy, as it is highly active in many human malignancies. A novel telomerase targeting approach combines short interfering RNA (siRNA) knockdown of endogenous human telomerase RNA (hTer) with expression of a mutant-template hTer (MT-hTer). Such combination MT-hTer/siRNA constructs induce a rapid DNA damage response, telomere uncapping, and inhibition of cell proliferation in a variety of human cancer cell lines. We tested which functional aspects of the protein catalytic component of telomerase [human telomerase reverse transcriptase (hTERT)] are required for these effects using human LOX melanoma cells overexpressing various hTERTs of known properties. Within 3 days of MT-hTer/siRNA introduction, both growth inhibition and DNA damage responses were significantly higher in the setting of wild-type hTERT versus catalytically dead hTERT or mutant hTERT that is catalytically competent but unable to act on telomeres. These effects were not attenuated by siRNA-induced knockdown of the telomeric protein human Rap1 and were additive with knockdown of the telomere-binding protein TRF2. Hence, the effects of MT-hTer/siRNA require a telomerase that is both catalytically competent to polymerize DNA and able to act on telomeres in cells. (Cancer Res 2006; 66(11): 5763-71)

This article has been cited by other articles:

				T. Xu, Y. Xu, C.-P. Liao, R. Lau, and A. Goldkorn Reprogramming Murine Telomerase Rapidly Inhibits the Growth of Mouse Cancer Cells In vitro and In vivo Mol. Cancer Ther., February 1, 2010; 9(2): 438 - 449. [Abstract] [Full Text] [PDF]

				B. A. Stohr and E. H. Blackburn ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells Cancer Res., July 1, 2008; 68(13): 5309 - 5317. [Abstract] [Full Text] [PDF]

				L. Kelland Targeting the Limitless Replicative Potential of Cancer: The Telomerase/Telomere Pathway Clin. Cancer Res., September 1, 2007; 13(17): 4960 - 4963. [Abstract] [Full Text] [PDF]

				Z.-T. Xin, A. D. Beauchamp, R. T. Calado, J. W. Bradford, J. A. Regal, A. Shenoy, Y. Liang, P. M. Lansdorp, N. S. Young, and H. Ly Functional characterization of natural telomerase mutations found in patients with hematologic disorders Blood, January 15, 2007; 109(2): 524 - 532. [Abstract] [Full Text] [PDF]